Blair William & Co. IL bought a new position in shares of Opko Health, Inc. (NASDAQ:OPK) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 17,071 shares of the biotechnology company’s stock, valued at approximately $112,000.

A number of other hedge funds also recently made changes to their positions in OPK. Capstone Asset Management Co. increased its position in Opko Health by 8.6% during the first quarter. Capstone Asset Management Co. now owns 17,646 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 1,400 shares during the period. Shell Asset Management Co. bought a new position in Opko Health during the first quarter worth $551,000. Wells Fargo & Company MN increased its position in Opko Health by 70.8% during the first quarter. Wells Fargo & Company MN now owns 699,650 shares of the biotechnology company’s stock worth $5,597,000 after acquiring an additional 290,084 shares during the period. Canada Pension Plan Investment Board bought a new position in Opko Health during the first quarter worth $2,197,000. Finally, Eqis Capital Management Inc. increased its position in Opko Health by 11.8% during the first quarter. Eqis Capital Management Inc. now owns 34,159 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 3,607 shares during the period. 22.46% of the stock is currently owned by institutional investors and hedge funds.

Shares of Opko Health, Inc. (NASDAQ:OPK) opened at 6.13 on Monday. The firm’s 50-day moving average is $6.24 and its 200-day moving average is $6.97. The firm’s market cap is $3.43 billion. Opko Health, Inc. has a 1-year low of $5.85 and a 1-year high of $12.15.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.02 EPS. On average, analysts anticipate that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.

WARNING: “Blair William & Co. IL Takes Position in Opko Health, Inc. (OPK)” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/11/blair-william-co-il-takes-position-in-opko-health-inc-opk.html.

In related news, CEO Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock in a transaction dated Friday, August 25th. The shares were bought at an average cost of $6.17 per share, with a total value of $154,250.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,935,427.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have bought 1,048,500 shares of company stock worth $6,660,438. 40.19% of the stock is currently owned by insiders.

A number of brokerages recently issued reports on OPK. Cantor Fitzgerald began coverage on shares of Opko Health in a research report on Thursday, August 17th. They set an “overweight” rating and a $20.00 target price on the stock. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 target price on shares of Opko Health in a research report on Monday, June 12th. Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Friday, July 21st. Barrington Research boosted their target price on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.28.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.